PL2500730T3 - ROZPUSZCZALNY RECEPTOR UROKINAZOWEGO AKTYWATORA PLAZMINOGENU (suPAR) JAKO WSKAŹNIK DIAGNOSTYCZNY ZAPALENIA O NIEWIELKIM NASILENIU - Google Patents
ROZPUSZCZALNY RECEPTOR UROKINAZOWEGO AKTYWATORA PLAZMINOGENU (suPAR) JAKO WSKAŹNIK DIAGNOSTYCZNY ZAPALENIA O NIEWIELKIM NASILENIUInfo
- Publication number
- PL2500730T3 PL2500730T3 PL12164660T PL12164660T PL2500730T3 PL 2500730 T3 PL2500730 T3 PL 2500730T3 PL 12164660 T PL12164660 T PL 12164660T PL 12164660 T PL12164660 T PL 12164660T PL 2500730 T3 PL2500730 T3 PL 2500730T3
- Authority
- PL
- Poland
- Prior art keywords
- supar
- low
- plasminogen activator
- diagnostic marker
- urokinase plasminogen
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 title 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87683806P | 2006-12-22 | 2006-12-22 | |
| DKPA200601709 | 2006-12-22 | ||
| US94707407P | 2007-06-29 | 2007-06-29 | |
| DKPA200700956 | 2007-06-29 | ||
| EP12164660.8A EP2500730B1 (en) | 2006-12-22 | 2007-12-21 | Soluble urokinase plasminogen activator receptor (suPAR) as diagnostic marker for low-grade inflammation |
| EP07858108.9A EP2115478B1 (en) | 2006-12-22 | 2007-12-21 | Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2500730T3 true PL2500730T3 (pl) | 2018-08-31 |
Family
ID=39358030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12164660T PL2500730T3 (pl) | 2006-12-22 | 2007-12-21 | ROZPUSZCZALNY RECEPTOR UROKINAZOWEGO AKTYWATORA PLAZMINOGENU (suPAR) JAKO WSKAŹNIK DIAGNOSTYCZNY ZAPALENIA O NIEWIELKIM NASILENIU |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8815519B2 (pl) |
| EP (2) | EP2500730B1 (pl) |
| AU (1) | AU2007337996B2 (pl) |
| CA (1) | CA2674521C (pl) |
| CY (1) | CY1120296T1 (pl) |
| DK (2) | DK2500730T3 (pl) |
| ES (2) | ES2456043T3 (pl) |
| GB (1) | GB2461410C (pl) |
| HU (1) | HUE037758T2 (pl) |
| LT (1) | LT2500730T (pl) |
| PL (1) | PL2500730T3 (pl) |
| PT (1) | PT2500730T (pl) |
| SI (1) | SI2500730T1 (pl) |
| TR (1) | TR201807733T4 (pl) |
| WO (1) | WO2008077958A2 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| ES2457822T3 (es) | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
| SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| JP5798037B2 (ja) * | 2008-11-06 | 2015-10-21 | ユニバーシティ オブ マイアミ | 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割 |
| US8349256B2 (en) * | 2008-11-21 | 2013-01-08 | Sysmex Corporation | Blood cell analyzer, blood cell analyzing method, and computer program product |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| EP2596349B1 (en) | 2010-07-23 | 2017-12-13 | President and Fellows of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| KR20130041961A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액에서 질환 또는 상태의 특징을 검출하는 방법 |
| EP2596116A4 (en) | 2010-07-23 | 2014-03-19 | Harvard College | METHODS FOR DETECTION OF AUTOIMMUNE OR IMMUNE-RELATED DISEASES / PATHOLOGIES |
| TW201209171A (en) | 2010-07-23 | 2012-03-01 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| AU2011280936A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| EP2707055B1 (en) | 2011-05-09 | 2019-10-23 | The University of Miami | Reducing soluble urokinase receptor in the circulation |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| AU2013274002A1 (en) | 2012-06-15 | 2015-02-05 | Harry Stylli | Methods of detecting diseases or conditions |
| US20150141260A1 (en) | 2012-06-15 | 2015-05-21 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| WO2014012043A1 (en) * | 2012-07-13 | 2014-01-16 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a risk factor in non-fabry heart disease subjects |
| US20140188442A1 (en) * | 2012-12-27 | 2014-07-03 | Pearson Education, Inc. | System and Method for Selecting Predictors for a Student Risk Model |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| EP3385717A3 (en) | 2013-03-09 | 2018-10-24 | Harry Stylli | Methods of detecting prostate cancer |
| EP3191846A4 (en) | 2014-09-11 | 2018-06-13 | Harry Stylli | Methods of detecting prostate cancer |
| CA2988179A1 (en) * | 2015-06-16 | 2016-12-22 | Quantum Dental Technologies Inc. | System and method of monitoring consumable use based on correlations with diagnostic testing |
| WO2017075268A1 (en) | 2015-10-27 | 2017-05-04 | Abbott Laboratories | Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease |
| FI20177098A1 (fi) | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| GB201802795D0 (en) * | 2018-02-21 | 2018-04-04 | Virogates As | Patient assessment method |
| RU2706548C1 (ru) * | 2019-01-31 | 2019-11-19 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ диагностики стадий вич-инфекции |
| EP3947433A4 (en) * | 2019-04-02 | 2022-11-23 | The Regents of The University of Michigan | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASES |
| CN111128398B (zh) * | 2020-03-30 | 2020-08-14 | 广州地理研究所 | 一种基于人口迁徙大数据的流行病感染人数估算方法 |
| WO2021204902A1 (en) | 2020-04-08 | 2021-10-14 | Virogates A/S | Sars-cov-2 infection risk assessment method |
| CN112630442A (zh) * | 2020-11-03 | 2021-04-09 | 浙江大学 | 一种血浆可溶性尿激酶型纤溶酶原激活物受体及其应用 |
| WO2023172886A2 (en) * | 2022-03-07 | 2023-09-14 | Rush University Medical Center | Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein |
| CN114334170A (zh) * | 2022-03-14 | 2022-04-12 | 天津云检医学检验所有限公司 | 一种代谢年龄预测模型及其在结直肠癌诊断中的应用 |
| CN114783607B (zh) * | 2022-05-10 | 2023-06-23 | 中南大学湘雅医院 | 一种手术输血风险预测模型及其网络计算器的构建方法 |
| CN116106535B (zh) * | 2023-04-11 | 2023-08-11 | 南京品生医学检验实验室有限公司 | 生物标志物组合在制备乳腺癌预测产品中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69033653T2 (de) | 1989-04-07 | 2001-06-07 | Cancerforskningsfonden Af 1989 | Plasminogen-aktivator-rezeptor vom urokinasetyp |
| ATE368854T1 (de) * | 1999-11-25 | 2007-08-15 | Jesper Eugen-Olsen | Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten |
| ATE361096T1 (de) | 2001-01-25 | 2007-05-15 | San Raffaele Centro Fond | Antikörper zur modulierung der upa/upar interaktion und deren verwendungen |
| GB0124145D0 (en) | 2001-10-08 | 2001-11-28 | Bayer Ag | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease |
| CA2568428C (en) | 2004-05-25 | 2020-12-29 | Attenuon, Llc | Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy |
| US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
-
2007
- 2007-12-12 US US12/520,718 patent/US8815519B2/en active Active
- 2007-12-21 AU AU2007337996A patent/AU2007337996B2/en active Active
- 2007-12-21 DK DK12164660.8T patent/DK2500730T3/en active
- 2007-12-21 WO PCT/EP2007/064497 patent/WO2008077958A2/en active Application Filing
- 2007-12-21 ES ES07858108.9T patent/ES2456043T3/es active Active
- 2007-12-21 GB GB0912351.4A patent/GB2461410C/en active Active
- 2007-12-21 DK DK07858108.9T patent/DK2115478T3/en active
- 2007-12-21 SI SI200732027T patent/SI2500730T1/en unknown
- 2007-12-21 TR TR2018/07733T patent/TR201807733T4/tr unknown
- 2007-12-21 ES ES12164660.8T patent/ES2670711T3/es active Active
- 2007-12-21 EP EP12164660.8A patent/EP2500730B1/en active Active
- 2007-12-21 PT PT121646608T patent/PT2500730T/pt unknown
- 2007-12-21 PL PL12164660T patent/PL2500730T3/pl unknown
- 2007-12-21 HU HUE12164660A patent/HUE037758T2/hu unknown
- 2007-12-21 EP EP07858108.9A patent/EP2115478B1/en active Active
- 2007-12-21 CA CA2674521A patent/CA2674521C/en active Active
- 2007-12-21 LT LTEP12164660.8T patent/LT2500730T/lt unknown
-
2014
- 2014-06-23 US US14/312,298 patent/US9645157B2/en active Active
-
2018
- 2018-05-29 CY CY20181100576T patent/CY1120296T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2500730A1 (en) | 2012-09-19 |
| AU2007337996B2 (en) | 2013-03-14 |
| WO2008077958A2 (en) | 2008-07-03 |
| TR201807733T4 (tr) | 2018-06-21 |
| PT2500730T (pt) | 2018-05-28 |
| ES2670711T3 (es) | 2018-05-31 |
| US9645157B2 (en) | 2017-05-09 |
| HUE037758T2 (hu) | 2018-09-28 |
| CA2674521C (en) | 2022-06-14 |
| DK2500730T3 (en) | 2018-05-28 |
| US20140370527A1 (en) | 2014-12-18 |
| DK2115478T3 (en) | 2014-03-10 |
| CY1120296T1 (el) | 2019-07-10 |
| SI2500730T1 (en) | 2018-08-31 |
| CA2674521A1 (en) | 2008-07-03 |
| ES2456043T3 (es) | 2014-04-21 |
| GB2461410B (en) | 2011-06-29 |
| US8815519B2 (en) | 2014-08-26 |
| EP2115478B1 (en) | 2014-01-22 |
| EP2500730B1 (en) | 2018-03-07 |
| GB2461410C (en) | 2018-06-20 |
| GB2461410A (en) | 2010-01-06 |
| WO2008077958A3 (en) | 2009-04-02 |
| US20100098705A1 (en) | 2010-04-22 |
| EP2115478A2 (en) | 2009-11-11 |
| GB0912351D0 (en) | 2009-08-26 |
| LT2500730T (lt) | 2018-05-10 |
| AU2007337996A1 (en) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE037758T2 (hu) | Szolúbilis urokináz plazminogén aktivátor receptor (suPAR) alacsony intenzitású gyulladás diagnosztikai markereként | |
| HK1200697A1 (en) | Therapeutic agent for pruritus | |
| HK1220631A1 (zh) | 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法 | |
| PL2117571T3 (pl) | Epitop receptora aktywatora plazminogenu typu urokinazy | |
| HK1167397A1 (zh) | 作為抗癌症劑的 -取代的喹唑酮衍生物 | |
| PL2007356T3 (pl) | Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonka | |
| EP2093237A4 (en) | ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
| EP2127671A4 (en) | THERAPEUTIC AGENT AGAINST CANCER | |
| IL194800A0 (en) | Pre-mixed, ready-to-use pharmaceutical compositions | |
| IL193203A0 (en) | Igf-ir antagonists as adjuvants for treatment of prostate cancer | |
| EP2240165A4 (en) | CARRIER COMPOSITIONS WITH SOLUBLE HYDROPHOBIC CORE FOR THE RELEASE OF THERAPEUTICS, MANUFACTURING METHOD AND USER METHOD THEREFOR | |
| WO2011130537A3 (en) | Pharmaceutical compositions and methods for digesting atherosclerotic plaques | |
| EP1980237A4 (en) | GELIFYING AGENT | |
| EP2410336A4 (en) | BREAST CANCER DIAGNOSTIC MARKER COMPRISING THERODOXIN-1 AS ACTIVE INGREDIENT AND BREAST CANCER DIAGNOSTIC KIT USING THE SAME | |
| EP2184073A4 (en) | AGAINST PROTEASE HEMMER RESISTANT CANCER THERAPEUTICS | |
| EP2018873A4 (en) | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | |
| EP2052726A4 (en) | FERTILITY AGENT | |
| EP2123295A4 (en) | THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA | |
| WO2010101903A3 (en) | Compositions, methods and kits for preparing plasminogen; and plasmin prepared therefrom | |
| EP2009007A4 (en) | VEGETABLE THERAPEUTIC AGENT FOR THE TREATMENT OF A MALIGNANT TUMOR | |
| EP2099303A4 (en) | THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY | |
| TWM295521U (en) | Structure of ties waistband, underwear having germanium effect | |
| RS56117B1 (sr) | Derivati 5-supstituisanog hinazolinona kao antikancer agensi | |
| GB0601818D0 (en) | Therapeutic agent | |
| PL380796A1 (pl) | Środek do flotacji węgla |